Head-To-Head Review: Apollomics (NASDAQ:APLM) & Dianthus Therapeutics (NASDAQ:DNTH)

Apollomics (NASDAQ:APLM) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Apollomics and Dianthus Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	0	0	1	0	3.00
Dianthus Therapeutics	0	0	8	2	3.20

Apollomics presently has a consensus price target of $2.00, indicating a potential upside of 1,349.28%. Dianthus Therapeutics has a consensus price target of $44.71, indicating a potential upside of 58.00%. Given Apollomics’ higher probable upside, analysts clearly believe Apollomics is more favorable than Dianthus Therapeutics.

Risk & Volatility

Apollomics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Valuation & Earnings

This table compares Apollomics and Dianthus Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$1.22 million	10.12	-$172.60 million	N/A	N/A
Dianthus Therapeutics	$4.12 million	201.69	-$43.56 million	($5.83)	-4.85

Dianthus Therapeutics has higher revenue and earnings than Apollomics.

Profitability

This table compares Apollomics and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Dianthus Therapeutics	N/A	-20.82%	-19.86%

Insider & Institutional Ownership

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Dianthus Therapeutics beats Apollomics on 9 of the 12 factors compared between the two stocks.

About Apollomics

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.